From Bench to Bedside: Ethical and Clinical Best Practices for Genome Editing Applications.

Area of Science:

• Biotechnology and Biomedical Sciences
• Genetics and Genomics
• Medical Ethics and Regulation

Background:

• Genome editing (GE) technologies, including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR)-based systems, have revolutionized medicine.
• CRISPR systems are currently the most accessible, versatile, and widely adopted GE technology.
• Despite GE's therapeutic potential for inherited and acquired disorders, clinical translation faces significant safety, ethical, and regulatory hurdles.

Purpose of the Study:

• To review the current scientific literature and regulatory agency recommendations for the responsible clinical application of genome editing.
• To highlight key considerations for patient safety, ethical practice, and regulatory compliance in GE-based therapies.
• To provide an overview of technical and regulatory challenges associated with GE's medical use.

Main Methods:

• Literature review of published scientific studies on genome editing.
• Analysis of guidance documents and recommendations from regulatory agencies like the FDA and EMA.
• Synthesis of information regarding safety, ethical considerations, and regulatory frameworks for clinical GE.

Main Results:

• GE technologies offer promising therapeutic avenues but present challenges such as off-target mutations and unintended cellular modifications.
• Regulatory agencies emphasize rigorous preclinical testing, patient monitoring, informed consent, and adherence to legal standards.
• Harmonized safety standards and bioethical considerations are crucial for the clinical advancement of GE.

Conclusions:

• The responsible clinical application of genome editing necessitates a comprehensive approach integrating scientific advancements with stringent safety protocols, ethical oversight, and regulatory compliance.
• Addressing technical challenges and navigating regulatory landscapes are essential for realizing the full therapeutic potential of GE.
• Patient safety and ethical practice must remain paramount throughout the development and deployment of genome editing therapies.